SEATTLE, April 16, 2021, (MEDGADGET) — Global Atrial Fibrillation Market
Atrial fibrillation, also known as A-fib or AF, is a state of quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure, and other heart-related complications. Atrial fibrillation is exemplified by rapid and abnormal beating of the heart. Most episodes of atrial fibrillation occur without any prior symptoms, or sometimes with a few symptoms, such as intermittent heart palpitations, lightheadedness, fainting, chest pain, and shortness of breath. Atrial fibrillation is linked with an elevated risk of heart failure, stroke, and dementia. Atrial fibrillation is one of the kinds of supraventricular tachycardia (SVT), which is an abnormally fast heart rhythm arising from improper electrical activity in the upper part of the heart. Significant risk factors associated with atrial fibrillation include valvular heart diseases, such as coronary artery disease, heart failure, congenital heart disease, cardiomyopathy, and high blood pressure. Valvular heart diseases mostly occur due to rheumatic fever, while high alcohol intake, thyrotoxicosis, and diabetes mellitus are other causes. The pulse and post-pulse measurement, via electrocardiogram (ECG), helps in the diagnosis of this condition.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/205
According to the Centers for Disease Control and Prevention (CDC), around 6.1 million individuals in the U.S. are reported to be suffering from atrial fibrillation, and the figure is estimated to increase with the growing geriatric population in the region. Around 2% of the population, below 65 years of age, is known to suffer from AF. Therefore, the global atrial fibrillation market is projected to witness significant growth, owing to rising prevalence of AF, which is primarily triggered by the escalating number of cases of health issues, such as diabetes, obesity, and hypertension. The geriatric population is more susceptible to this condition due to their weak immune system. In addition, rising adoption of catheter ablation procedures is expected to fuel the growth of the global atrial fibrillation market over the forecast period (2016–2024).
Global Atrial Fibrillation Market Taxonomy
On the basis of treatment type, the global atrial fibrillation market is segmented into:
- Non-pharmacological
- MAZE Surgery
- Catheter Ablation
- Electric Cardioversion
- Pharmacological
Based on the device type, the global atrial fibrillation market is bifurcated into:
- Catheter Ablation Devices
- Mapping and Recording Systems
- Access Devices
- Cardiac Monitors
- Intracardiac Echocardiography (ICE) Systems
- Left Atrial Appendage (LAA) and Closure Devices
Order a copy of Atrial Fibrillation Market Report 2021 @ https://www.coherentmarketinsights.com/insight/buy-now/205
Rising prevalence of atrial fibrillation, especially among the geriatric population, to propel the global atrial fibrillation market expansion
Growing adoption of catheter ablation, paired with advancements in technology, is expected to fuel the global atrial fibrillation market growth. However, the lack of skilled professionals and alternative options over AF healing devices are factors projected to hamper the global market growth in the foreseeable future. According to the National Center for Biotechnology Information (NCBI), the prevalence of AF is predicted to double in a span of two decades (2010–2030). Several government initiatives are working towards making AF treatment more accessible to the general populace. For instance, favorable regulatory steps, such as the ‘National Program for Prevention and Control of Diabetes, Cardiovascular Diseases and Stroke (NPDCS)’, undertaken by the government of India. This program is aimed at preventing and controlling premature mortality and morbidity from cardiovascular diseases, stroke, and diabetes mellitus. Such initiatives are likely to drive the global market growth during the forecast period.
Global Atrial Fibrillation Market – Regional Outlook
North America holds a dominant position in the global atrial fibrillation market, accounting for the largest market share. The market dominance is thus attributed to the high presence of advanced healthcare facilities and higher adoption of technologically advanced devices and treatment measures, especially in countries, including the U.S. and Canada. The Asia Pacific market is foreseen to witness tremendous growth over the forecast period, owing to the growing geriatric population in the region. Moreover, it is predicted that the demand for atrial fibrillation treatment and devices would increase substantially in countries such as China and India, owing to the advancements taking place in healthcare infrastructure and growing healthcare expenditure in the region.
Key Players & Significant Developments
Some of the major companies operating in the global atrial fibrillation market are Cardiofocus Inc., Biosense Webster Inc., Biotitic Se & Co. Kg, St. Jude Medical, Inc., Medtronic Inc., Carima Inc., Boston Scientific Corporation, Ncontact Inc., and Agricore Inc.
The major research institutes around the world are focused on developing novel approaches that aid in the diagnosis and treatment of atrial fibrillation. For instance, in August 2019, a team of researchers from the Mayo Clinic reported the development of a rapid, Artificial Intelligence (AI)-based test that can identify patients with an abnormal heart rhythm. Similarly, in July 2019, researchers from the Miller Family Heart and Vascular Institute at the Cleveland Clinic reported in the Journal of the American Heart Association (AHA) that retired NFL players were five times more likely to suffer from atrial fibrillation. In June 2019, researchers at Baylor College of Medicine reported in an AHA journal that loss of protein phosphatase 1 regulatory subunit ppp1r3a promotes atrial fibrillation.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837